Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma
-
- NAGASHIO Ryo
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University
-
- KUCHITSU Yuki
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University
-
- IGAWA Satoshi
- Department of Respiratory Medicine, School of Medicine, Kitasato University
-
- KUSUHARA Seiichiro
- Department of Respiratory Medicine, School of Medicine, Kitasato University
-
- NAOKI Katsuhiko
- Department of Respiratory Medicine, School of Medicine, Kitasato University
-
- SATOH Yukitoshi
- Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kitasato University
-
- ICHINOE Masaaki
- Department of Pathology, School of Medicine, Kitasato University
-
- MURAKUMO Yoshiki
- Department of Pathology, School of Medicine, Kitasato University
-
- SAEGUSA Makoto
- Department of Pathology, School of Medicine, Kitasato University
-
- SATO Yuichi
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University
Search this article
Abstract
<p>NAP1L1 is a key regulator of embryonic neurogenesis but its role in lung cancer remains unexplored. In this study, we investigated the relationship between NAP1L1 expression and the clinicopathological parameters and prognosis of non-small cell lung cancer patients. To this end, the expression of NAP1L1 in tumor samples was evaluated by immunohistochemistry. NAP1L1 expression was significantly associated with reduced differentiation (P = 0.00014), higher pathological TNM stages (P < 0.00001), lymph node metastasis (P < 0.00001), intrapulmonary metastasis (P = 0.02955), lymphatic invasion (P = 0.00019), vascular invasion (P = 0.00008) and poorer prognosis (P = 0.0008) of patients with adenocarcinoma. Moreover, multivariate analyses using the Cox-proportional hazards model confirmed that NAP1L1 expression increased the risk of death after adjusting for other clinicopathological factors (HR = 2.46, 95% CI, 1.22–4.96). Furthermore, NAP1L1 expression was identified as an independent poor prognostic factor in patients with resectable stage I lung adenocarcinoma. NAP1L1-siRNA-treated lung adenocarcinoma-derived A549 cells showed significant suppression of proliferation, migration, and invasion abilities. These findings suggest that NAP1L1 may be a novel predictive and prognostic marker in lung adenocarcinoma, particularly in those with stage I of the disease.</p>
Journal
-
- Biomedical Research
-
Biomedical Research 41 (3), 149-159, 2020-06-01
Biomedical Research Press